Humanwell Healthcare (Group) Co.,Ltd. Class A

Humanwell Healthcare (Group) Co.,Ltd. Class A

SSSE:600079
20.32
CNY
+0.13
(+0.64%)
1.99EPS
12.12P/E
31.29BMarket Cap
Apr 29Next Earn
Humanwell Healthcare (Group) Co.,Ltd. Class A
SSE:600079
(Shanghai Stock Exchange)

Recent

price

20.32

P/E

ratio

12.12

div

yld

3.02%

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
2.34
3.74
5.37
5.97
6.09
8
9.33
11.42
14.3
15.01
15.01
12.95
13.85
15.17
15.69
14.72
15
Revenue per Share
0.23
0.31
0.41
0.41
0.39
0.52
0.63
1.53
-1.81
0.58
0.73
0.83
1.54
1.32
0.82
1.14
1.58
Basic EPS, GAAP
-0.2
-0.48
-0.64
-0.41
-0.34
-0.41
-0.54
-1.21
-0.55
0.85
0.72
0.3
-0.42
0.01
0.71
1.1
- -
Free Cash Flow per Basic Share
0.07
0.09
0.19
0.22
0.24
0.33
0.35
0.42
0.79
0.67
0.52
0.42
0.38
0.36
0.78
0.65
0.61
Dividend per Share
2.07
2.69
3.06
4.11
4.47
6.13
7.81
9.99
8.05
7.5
6.87
7.93
9.21
10.44
10.8
11.59
12.48
Book Value per Share
1.72
2.23
1.76
2.72
2.9
4.38
2.88
2.79
2.98
2.58
4.88
5.64
6.93
8.28
8.75
9.75
10.67
Tangible Book Value per Share
941
969
990
1,007
1,158
1,257
1,321
1,352
1,303
1,453
1,378
1,587
1,613
1,617
1,622
1,627
1,633
Basic Weighted Avg Shares
2,205
3,621
5,317
6,010
7,052
10,054
12,331
15,446
18,634
21,807
20,680
20,549
22,338
24,525
25,435
23,962
24,491
Sales/Revenue/Turnover
17.11
15.35
14.28
14.8
13.78
11.3
11.31
11.51
10.94
12.26
13.95
13.01
13.03
14.75
13.01
15.96
16.72
Operating Margin (%)
43
62
89
127
165
254
422
517
547
578
681
679
748
812
1,025
1,030
- -
Depreciation Expense
216
300
406
418
452
654
832
2,069
-2,358
843
1,006
1,317
2,484
2,134
1,330
1,855
2,582
Net Income, GAAP
17.36
15.08
19.04
21.91
22.61
20.41
20.88
21.32
- -
24.05
19
16.33
10.35
16.8
26.6
18.45
16.86
Effective Tax Rate (%)
9.82
8.29
7.64
6.95
6.41
6.5
6.75
13.39
-12.65
3.86
4.86
6.41
11.12
8.7
5.23
7.74
10.54
Profit Margin (%)
436
742
1,342
1,874
1,740
2,223
1,546
1,911
1,200
1,438
3,735
2,594
4,285
6,409
6,518
9,300
11,515
Working Capital
34
227
965
1,058
1,639
1,551
3,987
5,065
3,874
4,073
5,263
3,337
1,903
1,705
1,264
2,473
2,274
LT Debt
2,328
3,139
3,650
5,080
5,728
9,182
11,983
16,606
14,328
13,997
12,955
15,652
17,942
20,099
20,693
22,006
23,667
Total Equity
9.76
10.79
9.66
8.53
7.18
6.93
6
10.18
- -
5.38
6.41
6.77
11.02
9.91
6.22
8.59
10.59
Return on Invested Capital (%)
5.54
6.26
6.75
5.44
4.92
5.72
5.33
9.69
- -
3.78
3.84
6.48
8.18
6.07
3.84
4.74
6.66
Return on Capital (%)
11.67
13.05
14.31
11.35
9.97
10.38
9.29
17.56
-19.31
8
9.69
11.18
17.75
13.31
7.67
10.16
13.34
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
6,317
5,458
5,631
LT Borrowings
2,596
2,720
2,239
LT Finance Leases
41
37
35
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,632
1,632
1,632
Market Capitalization
30,735
26,834
31,290

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
21,509
21,218
22,228
Cash, Cash Equivalents & STI
5,476
5,150
5,655
Accounts Receivable, Net
10,272
10,164
10,424
Inventories
3,401
3,442
3,645
Total Current Liabilities
11,197
10,916
10,713
Payables & Accruals
- -
- -
- -
ST Debt
6,317
5,458
5,631
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
10.24%
11.36%
6.35%
Free Cash Flow
1,218.46%
2,472.98%
56.22%
Net Income, GAAP
-4.72%
21.46%
39.53%
Sales/Revenue/Turnover
9.62%
3.16%
-5.79%
Total Cash Common Dividend
16.24%
16.17%
-16.84%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
6,367
6,494
6,282
6,292
25,435
2025
6,137
5,927
- -
6,079
23,962
2026
6,101
5,959
6,352
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.3
0.38
0.29
-0.16
0.82
2025
0.33
0.38
- -
0.1
1.14
2026
0.36
0.45
0.66
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.14
0.42
0.05
0.17
0.78
2025
0.05
0.2
- -
0.03
0.65
2026
0.03
0.04
0.51
- -
- -
Business
Humanwell Healthcare (Group) Co., Ltd. (600079.SS) researches, develops, produces and sells pharmaceutical products principally in China and internationally, with a focus on anesthetics, fertility-regulating drugs, steroid hormones, central nervous system medications, Uyghur ethnic medicines, skin topical drugs, respiratory system drugs, anti-infection drugs, traditional Chinese medicines, medical devices, over-the-counter medicines, herbal medicines and biological products; specific offerings include sufentanil citrate injection, remifentanil hydrochloride for injection, hydromorphone hydrochloride injection, nalbuphine hydrochloride injection, alfentanil hydrochloride injection, remimazolam besylate injection, mifepristone preparations, zuka wood particles, compound muniziqi granules, urokinase for injection, neomycin sulfate API preparations, progesterone API preparations, remazolam besylate for injection (RuiMa), fospropofol disodium for injection (LinBingFen) and snowbellleaf tickclover general flavone capsule (Guang Shi Tong). The company, founded in 1993 and headquartered in Wuhan, China, operates subsidiaries and facilities including EPIC Pharma and St. Louis R&D Center in the US, PuraCap Pharmaceuticals in New Jersey and Wuhan, YiChang Humanwell Pharmaceutical, Likang Pharmaceutical, Paion Pharma in Germany, Humanwell Pharma Mali and Afrique in West Africa, Humanwell Pharmaceutical Ethiopia, Xinjiang Xipa Pharmaceutical and a subsidiary in Uzbekistan; it maintains FDA-certified plants for oral solids, soft capsules and injections, with over 60 ANDA approvals, more than 500 R&D projects including 60 category 1 and 2 new drugs, 822 authorized patents and presence across Europe, the US, Japan, Russia, Australia, New Zealand, Mexico and other regions. Recent developments encompass a January 2025 restructuring investment agreement with Zhaoshang Innovation Technology Group Co., Ltd. for ¥11.8 billion, positioning it as the new controlling shareholder with a 23.70% stake through direct, indirect and trust acquisitions to resolve prior shareholder debt issues; regulatory approvals including US FDA tentative approval for a seizure treatment in September 2025, drug registration for a pain management injection in September 2025, nod for progesterone soft capsules in May 2025 and trial authorization for a pain drug in May 2025; alongside ongoing R&D in non-addictive analgesics, sustained-release microspheres, transdermal patches and anti-abuse formulations targeting anesthesia, analgesia and CNS diseases.[post:overview]